- Risk level
- High
- Risk-return
- Medium
- Start from
- €500
Funding has closed. The page stays up for reference; similar open projects are below.
Inrobics
Spain
Social AI for wellbeing and personalized rehabilitation
Key figures
- Valuation
- €3,500,000
- Start from
- €500
- Target
- €750,000
Capital at risk. Most startups fail; estimates are the platform's own claims. Shares are hard to sell before an exit.
Would AI invest?
AI 74 HighOur AI gives this project 74 out of 100: High. How the AI score works
Information, not personal investment advice. The AI score rates the documents the platform publishes, can be wrong, and does not predict returns.
AI review
AIInrobics Social Robotics — Crowdfunding Investor Memo
Inrobics builds Alma®, an AI system that runs on small robots, tablets and on-screen characters to guide people through physical and mental exercises — used with children in rehabilitation, patients recovering movement, and older adults in care.
Sector: Digital health / assistive-AI & social robotics · Stage: Seed / pre-Series A · HQ: Leganés (Madrid), Spain · Raise: €100K–€350K (platform disclosure)
|
ℹ️ Information, not investment advice. Capital at risk — you could lose the full amount invested. Full notes are at the end of this memo. |
Snapshot
|
1 · Is the price fair? 💶 |
2 / 5 — The €3.5M pre-money price is about 13 times last year's revenue (€261K). Health-AI companies with proven data and workflow integration change hands at roughly 4x–8x revenue (Nelson Advisors; Windsor Drake, 2026), so this entry price sits above the benchmarks we could find. |
|
2 · Can they reach an exit stage? ⭐ |
AI SCORE 74 / 100 — Good. Strongest evidence: a publicly verified founding team of three PhDs and a CE-marked medical product already used in 20 centres by 1,000+ people. Biggest gap: revenue fell from €414K (2024) to €261K (2025), and the €13.1M pipeline is not backed by signed contracts in the pack. |
|
3 · If they do, what could it pay? 🎯 |
Target ~10x over 5–7 years (the standard expectation for seed stage — the company sets no investor target). If a successful sale is reached, illustratively roughly 10x–20x before fees and future dilution. Method: typical health-tech sale multiples of 4x–8x revenue (Nelson Advisors; Windsor Drake, 2026) applied to a modest successful scale, measured against the €3.5M entry price. No comparable exits for this niche were found on record. |
How to read the score
Three answers, one honest note. The fairness score says whether the entry price is supported by the sector benchmarks we could find. The AI Score is our read on whether the company has the building blocks in place to reach a point where a sale or other exit can happen — it rates readiness on the evidence shown, not the chance of success, and even companies with every building block in place fail more often than they succeed, which is why crowdfunding only works as a small part of a spread-out portfolio. The returns range is an illustration of what a successful sale could pay, built from named sector benchmarks — not a forecast. Where something was not in the pack, it did not lower any score — it appears in the questions list instead, so you can ask the company directly before investing. The listing was reviewed by a licensed crowdfunding platform (Startupxplore) before going live. Nothing here is a recommendation.
What the score bands mean
|
85–100 · Excellent |
All key building blocks for reaching an exit stage are evidenced and strong — rare at this stage |
|
70–84 · Good |
Building blocks largely in place, with specific gaps — named in the questions section |
|
50–69 · Average |
Meaningful building blocks missing or weakly evidenced |
|
30–49 · Weak |
Several core building blocks absent, or the evidence points against them |
|
1–29 · Critical |
Fundamental building blocks are not visible in the evidence |
|
What we could check. We verified the founders' identities and credentials, the UC3M spin-off origin, the lead investor (Grow Venture Partners), prior grants and awards, and the CE-marked medical-software status against public sources. The revenue, margin, pipeline, MRR and cap-table figures rest on the company's own materials — see the questions section. |
At a glance
|
✅ Three reasons to look closer |
⚠️ Three reasons for caution |
|
|
|
Deal terms. No terms were identified in the reviewed documents that would prevent a crowdfund investor from sharing in the upside. On a sale, money contributed as share capital and premium is returned first, and the rest is split among all shareholders in proportion to their holdings. Full mechanics — including one feature worth checking (a €1 early-exit buy-back) — are at the end of this memo. |
🏢 What the company does
Inrobics Social Robotics is a spin-off of the Universidad Carlos III de Madrid (UC3M) that develops Alma®, an artificial-intelligence platform for physical, cognitive and emotional well-being. The company reports that Alma runs across different devices — humanoid robots, tablets and on-screen avatars — rather than depending on any single piece of hardware, guiding users through exercises and generating progress data for professionals. Its customers are clinics, hospitals, rehabilitation and early-intervention centres, schools and nursing homes (sold business-to-business and to the public sector), plus home users reached through care providers. It earns money mainly from software subscriptions and analytics, sometimes bundled with hardware, and reports €500K+ of revenue to date across 20 centres and 1,000+ users. The company operates primarily in Spain, with pilots and distributors in several other countries. This…
The full review covers the borrower or company, the security, the cash flow, the risks and a verdict. Sign in to read it.
Information, not personal investment advice. The AI score rates the documents the platform publishes, can be wrong, and does not predict returns.
Ask AI about this project
Sign in to ask the AI about this project's documents.
Sign inLike this project?
👍 Yes · 0 👎 No · 0
Comments · 0
- No comments yet.
The platform and similar projects
Offered on
Similar open projects
Kepplair Evolution
Sowefund
- Estimated return
- up to 7×
- platform's estimate
- Valuation
- €60,000,000
Raising €9m
From €500
See project
Wind Fisher
Sowefund
- Estimated return
- up to 10×
- platform's estimate
- Valuation
- €9,961,800
Raising €600k
From €1,000
See project
Blumana
Sowefund
- Estimated return
- up to 28×
- platform's estimate
- Valuation
- €2,799,571
Raising €750k
From €1,000
See project